liveBook · Manning

hERG potassium channel

As explained in Build AI Drug Discovery Pipelines

The hERG potassium channel is a cardiac ion channel whose drug blockade can disrupt electrical repolarization and cause cardiotoxicity.

The hERG potassium channel is a cardiac antitarget: drug-induced blockage can disrupt electrical repolarization, contribute to cardiotoxicity, and cause long QT syndrome or arrhythmia. Early screening therefore removes compounds with this liability while preserving uncertainty for experimental follow-up. section 3.1

A ligand-based screening workflow treats hERG blockage as a supervised classification problem:

  • Predict class 1 for a hERG blocker and class 0 for a non-blocker. section 3.1
  • Define blockers from experimental potency using IC50 < 40 μM, equivalent to pIC50 > 4.4. section 3.2.1
  • Exclude pIC50 from features because it defines the label, requires experiments, and may contain missing or inconsistent measurements. section 3.2.1
  • Compare machine-learning predictions with structural-alert filters and distinguish missed blockers from incorrectly rejected therapeutic compounds. section 3.1

Dataset and label

The hERG blockers dataset contains 587 records with SMILES, names, pIC50 values, class labels, and scaffold or random split assignments; 526 records have non-null pIC50 values. The class column supplies the training target, while split columns support alternative validation strategies. section 3.2.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines labels, leakage risks, uncertainty handling, failure costs, and benchmark baselines, but defers model construction.
Examples
Uses SMILES records, IC50-to-pIC50 conversions, structural-alert filters, and a 587-row hERG blockers dataset.
What it assumes
Defines antitargets, IC50, pIC50, and binary classes before using them in screening and modeling decisions.
What you can do after
Evaluate hERG-screening models against structural-alert baselines while deferring low-confidence compounds for experimental follow-up.
How it connects
Connects hERG blockage with antitargets, cardiotoxicity, long QT syndrome, pIC50, structural alerts, and ligand-based screening.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.